Evidence check: Pharmakogenetik Medicheck in the context of sleep

The question about a pharmacogenetic 'Medicheck' in the context of sleep is valid, but the evidence is mixed. Some genetic variants influence the metabolism of sleep aids (e.g., melatonin, benzodiazepines, Z‑drugs) or predisposition to sleep disorders. For instance, CYP2C9 and CYP2D6 status is linked to melatonin and certain hypnotic metabolism. Clock genes (e.g., PER3, CLOCK) may affect sleep architecture. However, the clinical utility of such tests for individual sleep is often limited: many studies show weak associations, and most commercial pharmacogenetic checks rely on population GWAS data without prospective validation in sleep contexts. Clear actionable recommendations beyond general sleep hygiene are lacking. Therefore, a Medicheck can serve as supplementary information but not as a standalone basis for treatment decisions. Caution is warranted against overblown marketing claims. A physician or sleep specialist should always be involved.